Daily Stock Analysis, DES, Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California., priceseries

Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.. Daily Stock Analysis
Stock Information
Open
26.89
Close
26.98
High
27.11
Low
26.80
Previous Close
26.79
Daily Price Gain
0.19
YTD High
28.47
YTD High Date
Feb 25, 2019
YTD Low
23.70
YTD Low Date
Jan 2, 2019
YTD Price Change
2.72
YTD Gain
11.21%
52 Week High
28.47
52 Week High Date
Feb 25, 2019
52 Week Low
22.80
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-0.61
52 Week Gain
-2.22%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 11. 2017
25.01
Oct 23. 2017
26.63
30 Trading Days
6.47%
Link
LONG
Jan 4. 2019
24.92
Feb 28. 2019
27.86
37 Trading Days
11.82%
Link
Company Information
Stock Symbol
DES
Exchange
NASDAQ
Company URL
http://www.dermira.com
Company Phone
650 421 7200
CEO
Thomas G. Wiggans
Headquarters
California
Business Address
275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001557883
About

Dermira, Inc. is a biopharmaceutical company that focuses on bringing differentiated products to dermatologists and patients. It also focuses on medical dermatology, a field that concentrates on therapeutic solutions to treat skin conditions, such as psoriasis, hyperhidrosis and acne. Dermira was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Description

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.